September 21, 2026 06:06 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Arvind Kejriwal, family ‘missing’ from Delhi voter list, claims Aam Aadmi Party | ‘No UPI above ₹2,000?’ Ghaziabad traders put up ‘cash only’ hoardings | Trump signs Russia sanctions bill: India faces fresh 100% tariff threat over Moscow oil | Caught using ChatGPT for exam answers, IIT Bombay student dies by suicide; students protest | Congress' Nandigram candidate arrested after Mamata's support amid TMC symbol row; Bengal bypoll gets chaotic | Gurugram murder shocker: Groom-to-be leaves sisters at Delhi restaurant to meet ex-colleague, found dead days later | Delhi horror: Teen allegedly gangraped, stabbed to death and dumped in field; dogs eat parts of body | TMC name, symbol frozen: EC tells rival factions to pick new identities ahead of Bengal bypolls | Married just 17 days ago: Hyderabad engineer mysteriously found dead at US home | ‘We will promote cash’: New UPI charge triggers trader backlash, Opposition protests
Serum Institute of India

Serum Institute seeks financial assistance from govt to boost capacity

| @indiablooms | Apr 08, 2021, at 04:00 am

New Delhi/IBNS: Adar Poonawalla, the CEO of world's largest vaccine manufacturer Serum Institute of India (SII), has told NDTV it needs Rs 3,000 crore in assistance from the Indian government to expand its production capacity which is currently "very stretched" in wake of the export restrictions imposed by the government last month.

Poonawalla stated that the Indian government pays it far less per shot of the vaccine than what is earned in exports, necessitating funding to boost the production capacity.

"This was never budgeted or planned initially, because we were supposed to export and get the funding from export countries but now that that is not happening, we have to find other innovative ways to build our capacity," Poonawalla said.

He admitted that SII is not able to supply the vaccine to every Indian who needs it and at the moment it is prioritising India's needs.

He said the Indian government is paying Rs 150 per shot which is profitable but not enough for reinvesting.

"The price that is set is profitable, however it is not profitable enough to re-invest substantially in building capacity," Poonawalla said.

SII has appealed to the government for financial help after restrictions were imposed on the exports of Covishield to battle a steep rise in cases at home.

Poorer countries as well as some rich nations relied heavily on the Serum Institute of India (SII) to vaccinate their citizens with the AstraZeneca vaccine.

Serum Institute produces over two million doses of Covishield per day at its current capacity.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.